Buckel P
Boehringer Mannheim GmbH, Department of Biotechnology, Penzterg, Germany.
Trends Pharmacol Sci. 1996 Dec;17(12):450-6. doi: 10.1016/s0165-6147(96)01011-5.
Recombinant therapeutic proteins have become increasingly important over the past ten years. Numerous products derived from 20 different proteins are already on the market. In this review Peter Buckel discusses the issues surrounding the use of recombinant proteins as therapeutic agents. The first generation proteins for therapy all occur naturally in humans. Protein engineering has brought forth a second generation of products with application-specific properties obtained by fusion, mutation or deletion. The third generation of therapeutic proteins is produced by patients themselves after transfer of the relevant genes. The first successful applications of this gene therapy represent a new milestone in medicine.
在过去十年中，重组治疗性蛋白质变得越来越重要。已有20种不同蛋白质衍生的众多产品上市。在这篇综述中，彼得·布克尔讨论了围绕使用重组蛋白质作为治疗剂的相关问题。第一代治疗性蛋白质在人类体内均天然存在。蛋白质工程催生了第二代产品，这些产品通过融合、突变或缺失获得了具有特定应用属性的特性。第三代治疗性蛋白质是在相关基因转移后由患者自身产生的。这种基因治疗的首次成功应用代表了医学上的一个新里程碑。
